Kayla Fazio, DO
Family Medicine · Orange Park, FLNPI 1376956219
Payments from drug & device makers
Across 274 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$978
- AstraZeneca$682
- AbbVie$632
- Amgen$610
- GSK$490
- Lilly USA, LLC$471
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,629100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $978 |
| AstraZeneca | 35 | $682 |
| AbbVie(2 entities) | 37 | $632 |
| Amgen | 19 | $610 |
| GSK | 16 | $490 |
| Lilly USA, LLC | 28 | $471 |
| Pfizer | 21 | $381 |
| Merck | 6 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $142 |
| Vivus LLC | 5 | $97 |
| Aimmune Therapeutics, Inc. | 4 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Medtronic | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $61 |
| Bayer | 3 | $55 |
| Biohaven Pharmaceuticals, Inc. | 3 | $51 |
| Boston Scientific | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Boehringer Ingelheim | 3 | $42 |
| Abbott | 2 | $35 |
| Exact Sciences | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Johnson & Johnson | 1 | $29 |
| Dynavax Technologies Corporation | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Gilead | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Exeltis, USA Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,629 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 89 | $163,636 |
| EliquisApixaban | 27 | $27,844 |
| RybelsusSemaglutide | 18 | $27,439 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 18 | $24,060 |
| JardianceEmpagliflozin | 20 | $22,254 |
| FarxigaDapagliflozin Propanediol | 11 | $18,683 |
| MounjaroTirzepatide | 14 | $15,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,317 |
| Omeprazole | 105 | $2,020 |
| Gabapentin | 73 | $1,954 |
| Atorvastatin Calcium | 217 | $1,907 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,784 |
| Levothyroxine Sodium | 168 | $1,623 |
| SynthroidLevothyroxine Sodium | 11 | $1,534 |
| Rosuvastatin Calcium | 135 | $1,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $978 | $191,074107 claims |
| Boehringer IngelheimTrijardy Xr, Jardiance | $42 | $46,31438 claims |
| PfizerEliquis | $381 | $27,84427 claims |
| AstraZenecaFarxiga | $682 | $18,68311 claims |
| Lilly USA, LLCMounjaro | $471 | $15,57414 claims |
| GSKTrelegy Ellipta | $490 | $11,31715 claims |
| AbbVieSynthroid | $632 | $1,53411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Orange Park
- Michael StephensOrange Park$4.2M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.